ATE505539T1 - Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren - Google Patents

Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren

Info

Publication number
ATE505539T1
ATE505539T1 AT04787726T AT04787726T ATE505539T1 AT E505539 T1 ATE505539 T1 AT E505539T1 AT 04787726 T AT04787726 T AT 04787726T AT 04787726 T AT04787726 T AT 04787726T AT E505539 T1 ATE505539 T1 AT E505539T1
Authority
AT
Austria
Prior art keywords
neural stem
stem cells
stem cell
methods
proliferation
Prior art date
Application number
AT04787726T
Other languages
English (en)
Inventor
Hideyuki Okano
James H Okano
Masanori Sakaguchi
H Mizusawa
S Ishibashi
Original Assignee
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio filed Critical Univ Keio
Application granted granted Critical
Publication of ATE505539T1 publication Critical patent/ATE505539T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04787726T 2003-09-09 2004-09-08 Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren ATE505539T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003317379 2003-09-09
PCT/JP2004/013043 WO2005026343A1 (ja) 2003-09-09 2004-09-08 神経幹細胞の生存及び／又は増殖及び神経突起伸張を促進する方法並びに促進剤、神経幹細胞を含む医薬組成物、検定方法、スクリーニング方法

Publications (1)

Publication Number Publication Date
ATE505539T1 true ATE505539T1 (de) 2011-04-15

Family

ID=34308479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787726T ATE505539T1 (de) 2003-09-09 2004-09-08 Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren

Country Status (6)

Country Link
US (1) US7785596B2 (de)
EP (1) EP1674566B1 (de)
JP (2) JP5099288B2 (de)
AT (1) ATE505539T1 (de)
DE (1) DE602004032248D1 (de)
WO (1) WO2005026343A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4997432B2 (ja) * 2006-02-10 2012-08-08 学校法人慶應義塾 神経幹細胞の増殖抑制剤
JP4925262B2 (ja) * 2006-04-05 2012-04-25 学校法人慶應義塾 シグナル伝達系活性化剤
WO2008036717A2 (en) * 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
CN101541954B (zh) 2006-11-30 2012-12-26 Medipost株式会社 含有人脐带血衍生的间充质干细胞的组合物诱导神经前体细胞或神经干细胞分化和增殖为神经细胞的用途
EP2108043A4 (de) * 2007-01-18 2010-04-21 Suomen Punainen Risti Veripalv Neue verfahren und reagentien zur produktion von zellen
US20100120142A1 (en) 2008-07-11 2010-05-13 Suomen Punainen Risti Veripalvelu Culture of human embryonic cells
AU2009267964A1 (en) * 2008-07-11 2010-01-14 Glykos Finland Oy Culture of cells
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
JP2012029684A (ja) * 2010-06-30 2012-02-16 Cell Aid Kenkyusho:Kk 細胞の製造方法
US9694049B2 (en) * 2011-08-11 2017-07-04 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Unitversity Of Nevada, Reno Methods for treating muscular dystrophy
EP3285797B1 (de) 2015-04-21 2020-11-11 Consejo Nacional de Investigaciones Científicas y Técnicas Gal-1-varianten mit immunmodulierenden eigenschaften und verfahren zur verwendung davon
AU2017340387A1 (en) 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
JPWO2024071223A1 (de) * 2022-09-28 2024-04-04

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
EP1122311A4 (de) * 1998-07-31 2002-04-17 Kirin Brewery Heilverfahren der neuropathie, welche als aktiven inhaltsstoff galektin-1 oder seine derivate beinhalten
EP1147126A4 (de) * 1998-12-11 2003-07-09 Salk Inst For Biological Studi Co-faktoren für trophische faktoren und methoden für deren verwendung
WO2001088100A1 (en) 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
ATE420101T1 (de) * 2001-04-20 2009-01-15 Children S Hospital Of Orange Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
JP2002325571A (ja) * 2001-04-27 2002-11-12 Purotekku:Kk 網膜の分化誘導方法
JP3566941B2 (ja) * 2001-05-31 2004-09-15 独立行政法人 科学技術振興機構 ＭｕｓａｓｈｉによるＮｕｍｂタンパク質発現抑制剤
CN1458273A (zh) * 2002-01-16 2003-11-26 中国医学科学院中国协和医科大学血液学研究所 人胎儿背根神经节干细胞的分离、制备及应用
US8043853B2 (en) * 2002-08-14 2011-10-25 The Regents Of The University Of Michigan Postnatal gut neural crest stem cells
AU2003278741B2 (en) * 2002-08-27 2008-02-14 Stemcells California Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations

Also Published As

Publication number Publication date
JPWO2005026343A1 (ja) 2007-11-08
JP5099288B2 (ja) 2012-12-19
DE602004032248D1 (de) 2011-05-26
US7785596B2 (en) 2010-08-31
EP1674566A1 (de) 2006-06-28
US20070098701A1 (en) 2007-05-03
EP1674566A4 (de) 2007-01-17
JP2012077092A (ja) 2012-04-19
WO2005026343A1 (ja) 2005-03-24
EP1674566B1 (de) 2011-04-13

Similar Documents

Publication Publication Date Title
ATE505539T1 (de) Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
Ohlendieck et al. Nitrogen fixation by diazotrophic cyanobacteria in the Baltic Sea and transfer of the newly fixed nitrogen to picoplankton organisms
Glas et al. Calcification acidifies the microenvironment of a benthic foraminifer (Ammonia sp.)
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
IL193495A0 (en) Culture medium containing kinase inhibitors and uses thereof
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
UA116618C2 (uk) СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
WO2012131733A3 (en) Media compositions for enriching cultures of stem cells
ATE510004T1 (de) In-vitro-techniken zur verwendung mit stammzellen
DE602007013695D1 (de) Leuchtende stammzellen und ihre verwendung
EP1687413B8 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
ATE551358T1 (de) Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1
ZA200807766B (en) Inhibition of GASC1
BR0317910A (pt) Uso de um fator hematopoiético; de um polinucleotìdeo que codifica o dito fato; de uma célula tronco neuronal; e de gcsf e/ou de derivados de gcsf; métodos para identificar um composto; composto assim identificado, bem como métodos para intensificar a viabilidade de uma cultura de célula neural
MX2010005079A (es) Metodos para medir la viabilidad celular sin usar celulas de control.
Bianchi et al. Microbial activities at the benthic boundary layer in the Aegean Sea
Tanvet et al. Corals adapted to extreme and fluctuating seawater pH increase calcification rates and have unique symbiont communities
Rodrigues de Faria et al. Late Eocene to Early Oligocene productivity events in the proto-Southern Ocean as drivers of global cooling and Antarctica glaciation
AR078804A1 (es) Metodos y placas de superficie modificada y composiciones para la fijacion el cultivo y el desprendimiento celular
FR2894594B1 (fr) Test predictif de reponse therapeutique du cancer du sein
WO2010056012A3 (en) Method for quantifying skin changes caused by six external evils and method for screening skin condition-improving materials using the same
ATE535611T1 (de) Verfahren zum screening des baff-suppressors oder inhibitors
Sperling et al. Patterns of radiocarbon uptake by a thermophilic blue‐green alga under varying conditions of incubation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties